HOME >> BIOLOGY >> NEWS
Burnham Institute for Medical Research announces affiliation with UC Santa Barbara

(La Jolla and Santa Barbara, California December 12, 2006) -- The Burnham Institute for Medical Research ("Burnham") has established an affiliation with the University of California, Santa Barbara led by internationally-renowned medical researcher Erkki Ruoslahti, M.D., Ph.D, the campus and the Institute announced today. Dr. Ruoslahti maintains his primary appointment as Distinguished Professor with the Burnham, and joins UCSB's Department of Molecular, Cellular and Developmental Biology as an adjunct Distinguished Professor.

At Burnham-UCSB, Ruoslahti has opened the "Vascular Mapping Center", which will focus on developing applications for vascular "zip codes," based on technology discovered in his laboratory. Vascular zip codes are molecular signatures in blood and lymphatic vessels ("vasculature") that are specific to individual tissues and disease sites. Ruoslahti has discovered ways to selectively target drugs to tumor blood vessels in mice and suppress the growth of those tumors. He has also found a way to selectively target the lymphatic vessels in tumors. The hope is that this very specific delivery of therapeutics to tumor blood and lymphatic vessels will increase the efficacy of cancer therapies and decrease side effects.

Targeting peptides discovered in Ruoslahti's laboratory are providing the platform for integrating nanotechnologies into the design of new therapies for cancer and heart disease. Ruoslahti and others at Burnham contribute a key component to the Center of Cancer Nanotechnology Excellence at the University of California, San Diego founded with $20 million from the National Cancer Institute.

A partnership of 25 scientists, primarily from Burnham and UCSB, has been recognized by the National Institutes of Health as a "Program of Excellence in Nanotechnology", awarding a $13 million grant to design nanotechnologies that detect, monitor, treat, and eliminate "vulnerable" plaque, the probable cause of deat
'"/>

Contact: Nancy Beddingfield
nbeddingfield@burnham.org
858-646-3146
Burnham Institute
12-Dec-2006


Page: 1 2

Related biology news :

1. NIH awards $7.39 million to Burnham neurobiologists
2. CIRM awards $6M to Burnham Institute
3. CIRM awards $5.9 million to Burnham Institute
4. Burnham awarded $12.7 million from NIH to create one of nations top neuroscience research centers
5. Burnham Institute for Medical Research & UC San Diego establish Joint Center for Molecular Modeling
6. Burnham to collaborate on NCI-funded task force to find molecular signature for prostate cancer
7. Burnham Institute to collaborate in NCI funded Center of Cancer Nanotechnology Excellence
8. NFCR - Prostate Cancer Foundation unite with Burnham Institute to expedite cancer drug discovery
9. NIH selects Burnham Institute for Exploratory Center for Human Embryonic Stem Cell Research
10. Anthrax inhibitors identified by Burnham team
11. NIH awards $11.9 M to The Burnham Institute to establish the San Diego Chemical Screening Center

Post Your Comments:
(Date:5/16/2013)... 17, 2013) Illustrating a commitment to the ... Gastroenterological Association (AGA) Research Foundation has announced the ... Fellowship Award recipients. Supported by the National Institute ... this new award helps underrepresented minority students to ... nutrition research. , "By establishing this new award, ...
(Date:5/16/2013)... closer to a fast food restaurant had a higher ... away from fast food, according to researchers at The ... association was particularly strong among those with a lower ... the American Journal of Public Health indicates ... food restaurant, and among lower-income African-Americans, the density, or ...
(Date:5/16/2013)... nanoparticles developed at MIT may someday eliminate the ... constantly monitor their blood-sugar levels and inject themselves ... sense glucose levels in the body and respond ... replacing the function of pancreatic islet cells, which ... Ultimately, this type of system could ensure that ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3
(Date:5/20/2013)... , Md. and BALTIMORE , ... (BHI), a regional private-public partnership focusing on ... early-stage funding in Central Maryland ... Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) for ... National Heart, Lung and Blood Institute ...
(Date:5/20/2013)... 2013 Rhythm announced today the results of ... company,s novel ghrelin agonist for the treatment of diabetic ... that RM-131 significantly accelerates early gastric emptying and reduces ... with diabetic gastroparesis. The findings were presented at the ... and recently published in Clinical Gastroenterology ...
(Date:5/20/2013)... WILMINGTON, Del. (PRWEB) May 20, 2013 ... named 14 young faculty members to its 2013 ... three years, the company will provide this outstanding ... their work in advancing basic science to meet ... is designed to help promising young and untenured ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 In Early ... the field of biotoxin related illnesses , announced his ... country able to advance his protocol for treating Chronic ... became the third physician to achieve certification in the ... Physicians, able to practice the Shoemaker Protocol in other ...
Breaking Biology Technology:BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2
Cached News: